Literature DB >> 25908969

Bone remodeling markers and bone metastases: From cancer research to clinical implications.

Arlindo Ferreira1, Irina Alho2, Sandra Casimiro2, Luís Costa1.   

Abstract

Bone metastasis is a frequent finding in the natural history of several types of cancers. However, its anticipated risk, diagnosis and response to therapy are still challenging to assess in clinical practice. Markers of bone metabolism are biochemical by-products that provide insight into the tumor-bone interaction, with potential to enhance the clinical management of patients with bone metastases. In fact, these markers had a cornerstone role in the development of bone-targeted agents; however, its translation to routine practice is still unclear, as reflected by current international guidelines. In this review, we aimed to capture several of the research and clinical translational challenges regarding the use of bone metabolism markers that we consider relevant for future research in bone metastasis.

Entities:  

Year:  2015        PMID: 25908969      PMCID: PMC4407509          DOI: 10.1038/bonekey.2015.35

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN: 2047-6396


  74 in total

Review 1.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

Authors:  D F Hayes; R C Bast; C E Desch; H Fritsche; N E Kemeny; J M Jessup; G Y Locker; J S Macdonald; R G Mennel; L Norton; P Ravdin; S Taube; R J Winn
Journal:  J Natl Cancer Inst       Date:  1996-10-16       Impact factor: 13.506

2.  The effects of bazedoxifene in the ovariectomized aged cynomolgus monkey.

Authors:  Susan Y Smith; Jacquelin Jolette; Luc Chouinard; Barry S Komm
Journal:  J Bone Miner Metab       Date:  2014-03-16       Impact factor: 2.626

3.  Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.

Authors:  Luis Costa; Laurence M Demers; A Gouveia-Oliveira; J Schaller; Eduardo B Costa; Miguel C de Moura; Allan Lipton
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

4.  Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.

Authors:  Ioannis Kyvernitakis; Tilman D Rachner; Anja Urbschat; Olaf Hars; Lorenz C Hofbauer; Peyman Hadji
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-07       Impact factor: 4.553

5.  Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer.

Authors:  Eitan Amir; Orit Freedman; Lindsay Carlsson; George Dranitsaris; George Tomlinson; Andreas Laupacis; Ian F Tannock; Mark Clemons
Journal:  Am J Clin Oncol       Date:  2013-10       Impact factor: 2.339

6.  Does methamphetamine affect bone metabolism?

Authors:  Masafumi Tomita; Hironobu Katsuyama; Yoko Watanabe; Toshiko Okuyama; Shigeko Fushimi; Takaki Ishikawa; Masayuki Nata; Osamu Miyamoto
Journal:  Toxicology       Date:  2014-02-26       Impact factor: 4.221

7.  Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.

Authors:  Allan Lipton; Richard Cook; Fred Saad; Pierre Major; Patrick Garnero; Evangelos Terpos; Janet E Brown; Robert E Coleman
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

8.  Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.

Authors:  R Coleman; R de Boer; H Eidtmann; A Llombart; N Davidson; P Neven; G von Minckwitz; H P Sleeboom; J Forbes; C Barrios; A Frassoldati; I Campbell; O Paija; N Martin; A Modi; N Bundred
Journal:  Ann Oncol       Date:  2012-10-09       Impact factor: 32.976

9.  Breast-cancer adjuvant therapy with zoledronic acid.

Authors:  Robert E Coleman; Helen Marshall; David Cameron; David Dodwell; Roger Burkinshaw; Maccon Keane; Miguel Gil; Stephen J Houston; Robert J Grieve; Peter J Barrett-Lee; Diana Ritchie; Julia Pugh; Claire Gaunt; Una Rea; Jennifer Peterson; Claire Davies; Victoria Hiley; Walter Gregory; Richard Bell
Journal:  N Engl J Med       Date:  2011-09-25       Impact factor: 91.245

10.  International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis.

Authors:  Samuel Vasikaran; Cyrus Cooper; Richard Eastell; Andrea Griesmacher; Howard A Morris; Tommaso Trenti; John A Kanis
Journal:  Clin Chem Lab Med       Date:  2011-05-24       Impact factor: 3.694

View more
  24 in total

Review 1.  Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability.

Authors:  P Szulc; K Naylor; N R Hoyle; R Eastell; E T Leary
Journal:  Osteoporos Int       Date:  2017-06-19       Impact factor: 4.507

Review 2.  [Diagnostics in osteology].

Authors:  F Jakob; F Genest; L Seefried; E Tsourdi; C Lapa; L C Hofbauer
Journal:  Internist (Berl)       Date:  2016-07       Impact factor: 0.743

3.  Enrichment of Collagen Fragments Using Dimeric Collagen Hybridizing Peptide for Urinary Collagenomics.

Authors:  Julian L Kessler; Yang Li; Jaime Fornetti; Alana L Welm; S Michael Yu
Journal:  J Proteome Res       Date:  2020-06-16       Impact factor: 4.466

4.  N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.

Authors:  Arlindo R Ferreira; Irina Alho; Ning Shan; Margarida Matias; Mariana Faria; Sandra Casimiro; Kim Leitzel; Suhail Ali; Allan Lipton; Luís Costa
Journal:  Oncologist       Date:  2016-08-17

Review 5.  Severe and refractory hypocalcaemia secondary to osteoblastic bone metastases in bladder signet ring carcinoma: A case report and literature review.

Authors:  Wanling Zeng; Du Soon Swee
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

Review 6.  The Effect of Selected Herbal Medicines on Bone Turnover Markers: A Systematic Review and Meta-Analysis.

Authors:  Hanie Kheiridoost-Langaroodi; Seyed Kazem Shakouri; Mahdi Amirpour; Amir Mehdi Iranshahi; Azizeh Farshbaf-Khalili
Journal:  J Family Reprod Health       Date:  2022-03

Review 7.  Targeting collagen for diagnostic imaging and therapeutic delivery.

Authors:  Hendra Wahyudi; Amanda A Reynolds; Yang Li; Shawn C Owen; S Michael Yu
Journal:  J Control Release       Date:  2016-01-07       Impact factor: 9.776

8.  The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club.

Authors:  E Cavalier; P Bergmann; O Bruyère; P Delanaye; A Durnez; J-P Devogelaer; S L Ferrari; E Gielen; S Goemaere; J-M Kaufman; A Nzeusseu Toukap; J-Y Reginster; A-F Rousseau; S Rozenberg; A J Scheen; J-J Body
Journal:  Osteoporos Int       Date:  2016-03-30       Impact factor: 4.507

9.  A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer.

Authors:  Jianda Huang; Tongjie Gu; Jun Ying
Journal:  Int J Clin Oncol       Date:  2017-07-04       Impact factor: 3.402

10.  The Lyme Disease Pathogen Borrelia burgdorferi Infects Murine Bone and Induces Trabecular Bone Loss.

Authors:  Tian Tian Tang; Lucia Zhang; Anil Bansal; Marc Grynpas; Tara J Moriarty
Journal:  Infect Immun       Date:  2017-01-26       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.